USFDA approval for anti-cholesterol tablet by Lupin
Advertisement
Lupin will now market a generic version of Teva’s Fenofibrate Tablets in the American market
Pharmaceutical major Lupin Ltd recently announced that it has received the approval from USFDA to market the generic version of Teva’s Fenofibrate Tablets in the American market, an anti-cholesterol tablet. A generic version of Teva's Fenofibrate Tablets, 54 mg and 160 mg, has a US sales of $156 million.
"Lupin's US subsidiary, Lupin Pharmaceuticals Inc. would commence promoting the product shortly in the US," the company said, as reported by IANS.
According to Lupin, its Fenofibrate tablets 54 mg and 160 mg are the AB rated generic equivalent of the current reference listed drug, Fenofibrate Tablets 54 mg and 160 mg of Teva.
"It is indicated as an adjunct to diet to reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia and for treatment of adult patients with severe hypertriglyceridemia," the statement said.
Pharmaceutical major Lupin Ltd recently announced that it has received the approval from USFDA to market the generic version of Teva’s Fenofibrate Tablets in the American market, an anti-cholesterol tablet. A generic version of Teva's Fenofibrate Tablets, 54 mg and 160 mg, has a US sales of $156 million.
"Lupin's US subsidiary, Lupin Pharmaceuticals Inc. would commence promoting the product shortly in the US," the company said, as reported by IANS.
According to Lupin, its Fenofibrate tablets 54 mg and 160 mg are the AB rated generic equivalent of the current reference listed drug, Fenofibrate Tablets 54 mg and 160 mg of Teva.
"It is indicated as an adjunct to diet to reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia and for treatment of adult patients with severe hypertriglyceridemia," the statement said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.